TG Therapeutics, Inc.
TGTX
Rang in Aktien
#2402
Based in New York City and established in 1993, TG Therapeutics, Inc. is a... Based in New York City and established in 1993, TG Therapeutics, Inc. is a biopharmaceutical company that has advanced to the commercial stage. Its core mission revolves around the acquisition, advancement, and marketing of novel therapeutic solutions. The company's focus areas specifically include B-cell related cancers (malignancies) and various autoimmune disorders. Among its significant investigational therapeutic candidates is Ublituximab, a distinctive glycoengineered monoclonal antibody currently undergoing evaluation. It targets B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and the relapsing forms of multiple sclerosis. Another compound in its pipeline is Umbralisib, an orally administered inhibitor designed to block PI3K-delta and CK1-epsilon enzymes. This treatment is being investigated for its effectiveness against CLL, marginal zone lymphoma, and follicular lymphoma. TG Therapeutics is also developing Cosibelimab, an IgG1 human monoclonal antibody that functions by binding to programmed death-ligand 1 (PD-L1) and subsequently preventing its interaction with PD-1 and B7.1 receptors. Furthermore, the company is advancing TG-1701, an oral, covalently-bound Bruton's tyrosine kinase (BTK) inhibitor, notably more selective for BTK compared to ibrutinib in laboratory screenings. Completing this clinical-stage portfolio is TG-1801, a bispecific antibody engineered to simultaneously target CD47 and CD19. Beyond its clinical-stage assets, the company possesses various licensed preclinical programs, including those addressing BET, interleukin-1 receptor associated kinase-4, and GITR. To enhance its research and development capabilities, TG Therapeutics has forged collaboration agreements with entities such as Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company also maintains strategic alliances with partners including LFB Biotechnologies S.A.S, GTC Biotherapeutics, LFB/GTC LLC, Ildong Pharmaceutical Co. Ltd., and Rhizen Pharmaceuticals, S A.
Aktienkurs
$53.25
Marktkapitalisierung
$8.15B
Veränderung (1 Tag)
-1.33%
Veränderung (1 Jahr)
53.59%
Land
US
Handel TG Therapeutics, Inc. (TGTX)
Kategorie
Healthcare
Operative Marge für TG Therapeutics, Inc. (TGTX)
Operative Marge zum October 2026 TTM: 17.05%
Laut den neuesten Finanzberichten und dem Aktienkurs von TG Therapeutics, Inc. beträgt die aktuelle operative Marge (TTM) 17.05%. Am Ende des Jahres 2023 lag die operative Marge bei 8.83%.
Historie der operativen Marge von TG Therapeutics, Inc. von 2000 bis 2026
Operative Marge zum Jahresende
| Jahr | Operative Marge | ändert |
|---|---|---|
| 2026 (TTM) | 17.05% | 33.83% |
| 2024 | 12.74% | 44.28% |
| 2023 | 8.83% | -100.13% |
| 2022 | -6,924.20% | 34.34% |
| 2021 | -5,154.28% | -97.14% |
| 2020 | -179,996.05% | 61.84% |
| 2019 | -111,220.39% | -3.06% |
| 2018 | -114,736.84% | 47.28% |
| 2017 | -77,904.56% | 50.33% |
| 2016 | -51,823.47% | 24.99% |
| 2015 | -41,461.87% | 13.39% |
| 2014 | -36,566.96% | 142.62% |
| 2013 | -15,071.43% | -89.33% |
| 2012 | -141,196.45% | 0.00% |
| 2011 | 0.00% | 0.00% |
| 2010 | 0.00% | 0.00% |
| 2009 | 0.00% | 0.00% |
| 2008 | 0.00% | 0.00% |
| 2007 | 0.00% | 0.00% |
| 2006 | 0.00% | 0.00% |
| 2005 | 0.00% | 0.00% |
| 2004 | 0.00% | 0.00% |
| 2003 | 0.00% | -100.00% |
| 2002 | -310.58% | 171.06% |
| 2001 | -114.58% | 94.17% |
| 2000 | -59.01% | 0.00% |
Operative Marge vergleichbarer Unternehmen oder Wettbewerber
| Unternehmen | Operative Marge | Differenz der operativen Marge | Land |
|---|---|---|---|
| 38.59% | -97.74% |
US
|
|
| -149.01% | -108.74% |
US
|
|
| 25.57% | -98.50% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -98.31% |
NL
|
Was ist die operative Marge eines Unternehmens?
Die operative Marge ist ein wichtiger Indikator zur Bewertung der Rentabilität eines Unternehmens. Höhere operative Margen sind in der Regel besser, da sie zeigen, dass ein Unternehmen seine Produkte oder Dienstleistungen mit deutlichem Gewinn über den Produktionskosten verkauft. Die operative Marge wird berechnet, indem der Gewinn des Unternehmens durch seinen Umsatz geteilt wird.